Literature DB >> 9623522

Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia.

K Tada1, Y Okuda, K Yamashita.   

Abstract

We describe 3 cases of malignant pheochromocytoma with multiple metastases which were treated with cyclophosphamide, vincristine and dacarbazine (CVD) combination chemotherapy and alpha-methyl-p-tyrosine. Case 1 was operated on first but hypercatecholaminemia could not be completely controlled. Cases 2 and 3 received chemotherapy, CVD combination chemotherapy and/ or alpha-methyltyrosine and good control of hypercatecholaminemia was attained. In all cases it was possible to control hypercatecholaminemia during most of the time they were administered a-methyltyrosine despite the presence of tumors. None of the patients suffered hypertension crises. In our patients treatment with CVD plus a-methyl-p-tyrosine proved to be safe and ameliorated the clinical course.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9623522     DOI: 10.1159/000023190

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  4 in total

1.  Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas.

Authors:  Dhaval Patel; Amit Mehta; Naris Nilubol; William Dieckmann; Karel Pacak; Electron Kebebew
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

Review 2.  [Pheochromocytoma - still a challenge].

Authors:  N Reisch; M K Walz; Z Erlic; H P H Neumann
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

Review 3.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

Review 4.  Development of early diagnosis of Parkinson's disease: Illusion or reality?

Authors:  Michael Ugrumov
Journal:  CNS Neurosci Ther       Date:  2020-06-29       Impact factor: 7.035

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.